CSF1 and neoplasm: We found that tumor cell-specific CSF-1 inhibition significantly increased VEGF-A levels in the TMEM doorway macrophage compared to control treated mice (Fig. 5G), consistent with the in vitro finding where CSF-1 signaling blockade prevented VEGF-A secretion from macrophages (Fig. 3).